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This paper reviews a clinical case report that warrants the use of proton-pump inhibitors 
(PPI)s, according to current guidelines. It examines the cost benefit of this treatment and 
evaluates adverse outcomes associated with both short and long-term PPI use through a 
compilation of literature review. It further examines ways to minimize inappropriate PPI 
use, including minimizing dosages, utilizing lifestyle factors, step down therapy, 
intermittent therapy, and on-demand therapy according to guidelines. Review of the 
importance of reevaluating PPI use in the primary care setting, especially amongst older 
adults as described in the clinical case, is discussed. Implementation of these 
recommendations for addressing inappropriate PPI use in primary care will likely 
decrease the risks of adverse outcomes. 
Keywords: Gastro-esophageal Reflux Disease, Proton Pump Inhibitors, Step-Down 















An elderly female presents to the clinic with symptoms associated with gastro-
esophageal reflux disease (GERD), which warrants empiric treatment according to 
current guidelines with proton pump inhibitors (PPIs). She is otherwise healthy with her 
only chronic medical condition being hypertension. After prescribing omeprazole 20mg 
to be taken daily, she is instructed to follow-up in the clinic at which time reevaluation of 
her symptoms will take place. In anticipatory case management for this patient, the 
provider questions whether or not to continue the PPI at the follow-up appointment.  
This paper addresses this question by examining appropriate proton-pump 
inhibitor use and its risk-benefit analysis for patients in the primary care setting with 
GERD. Although current guidelines recommend PPI use due to their high efficacy in 
treatment of GERD, they also suggest limiting this treatment to eight weeks as initial 
therapy (Katz, Lauren, & Marcelo, 2013; Iwakiri, Kinoshita, Habu, et al., 2016). Despite 
this recommendation, few clinicians follow these guidelines, and PPI prescriptions 
continue to rise with most being repeat scripts for long-term therapy (Haastrup, Paulsen, 
Begtrup, Hansen, et al., 2014; Heidelbaugh, Kim, Chang, & Walker, 2012). In addition, it 
is estimated that 25% to 70% of people are inappropriately prescribed a PPI (Boghossian, 
Rahid, Thompson, Welch, et al., 2017). Literature has also suggested that proton pump 
inhibitors, which were initially viewed to have little to no adverse effects, are not as safe 
as originally thought. PPI use has been associated with enteric infections, pneumonia, 
bone fractures, nutrient malabsorption, chronic kidney disease, and dementia (Walsh, 
Kwan, Marr, et al., 2016; Wilsdon, Hendrix, Thynne, et al., 2017). Some of these 
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conditions have been shown to gain increased risk with higher dosages and/or longer 
terms of therapy (Freedberg, Kim, & Yang, 2017; Harrison, 2016). Yet, given the risks 
and common overutilization of proton-pump inhibitors, providers still often neglect to 
reevaluate patients at follow-up appointments for the need of PPIs for symptom 
management. 
The purpose of this paper is to examine ways to minimize inappropriate PPI use 
in the primary care setting in order to decrease the chance of adverse outcomes. 
Evaluation of de-prescribing, step-down therapy, minimizing dosages and treatment 
lengths, and alternative lifestyle factors are evaluated as options for effectively treating 
GERD symptoms. Managing GERD with these options are anticipated to minimize 




E.L, an 88-year-old female, presented to her primary care provider (PCP) with a 
chief complaint of a “cough that won’t go away.” She was treated for bronchitis about 
two months prior to her visit at a separate facility, which was around the same time that 
her symptoms began. She describes her cough as “irritating” with sensation “in the 
middle” of her chest. Her cough is present daily, worse at night, and associated with a 
“sour taste” in her mouth, a sore throat, and a “burning” in her chest. She denies 
production or hemoptysis. She has tried a humidifier, cough syrup, and “inhalers” thus far 
with no symptom relief. She denies any exposure to anyone who has been sick.    
When asked about similar symptomology in the past, E.L denies having anything 
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comparable to her presentation at this appointment. Further investigation does reveal a 
history of “heartburn” for which she takes Tums. She also mentions drinking “a pot of 
coffee” every morning and frequently eating after eight p.m. prior to going to bed in the 
evening. E.L is not particularly concerned about the severity of this cough; however, she 
is slightly bothered with its interruption of sleep.  
E.L’s past medical history includes hypertension, which is controlled with 
lisinopril 10mg once daily by mouth. E.L states she has been on this medication “for 
years” and has had no issues with it since its start. She is up-to-date on current 
immunizations, including seasonal influenza. Patient is unaware of any family history 
regarding gastro-esophageal reflux disease (GERD), although she does mention a history 
of heart disease, diabetes, and colon cancer in various first and second-degree relatives. 
E.L’s social history includes a ½ pack a day history of cigarette use “for many 
years” with cessation of all tobacco products “about ten years ago.” Alcohol consumption 
reveals “occasional use, maybe 1-2 beers a night.” She denies any illicit drug use. She is 
a retired female who lives locally with her adult daughter. E.L’s full history of presenting 
illness, review of systems and pertinent negatives can be found in her Electronic Medical 
Record (EMR) as outlined in Appendix A. 
Exam and Diagnostics 
 The physical examination reveals vital signs within normal limits with mental 
status and orientation intact. Head, eyes, ears, nose, throat, and neck assessments are all 
unremarkable. Skin is warm, dry, and intact throughout with no rashes apparent. Lungs 
are clear with respirations of regular rate and rhythm. Cough noted in middle of the chest 
appears dry in nature. Heart is of regular rate and rhythm, peripheral pulses are +2 
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throughout, and no lower extremity edema noted. Abdominal exam reveals a soft, non-
tender abdomen with bowel sounds throughout. There is no organomegaly noted. A chest 
x-ray obtained with this visit is unremarkable. Details of physical exam are listed in 
Appendix A. 
Treatment and Follow Up 
E.L is diagnosed with gastro-esophageal reflux disease and is prescribed 
omeprazole 20mg to be taken once daily. Her PCP provides additional education in the 
appropriateness of taking this prescription along with a thorough discussion of adverse 
side effects. E.L is also provided with a list of lifestyle changes to include diet, exercise 
and weight loss, elevation of the head of her bed, and avoidance of food consumption 
close to bedtime. She is instructed to return to the clinic in eight weeks for follow-up and 
further discussion of her GERD.  
Literature Review 
The key to all medication prescriptions is to ensure that the benefits of the 
medication outweigh the costs. Each medication added to a patient’s regimen, however, 
already increases risks associated with its own side effects and many times, 
polypharmacy. In the clinical case presented above, this is exactly the situation at hand as 
E.L begins to extend her medication list to include the appropriately prescribed PPI for 
her treatment of GERD. The addition of this medication for an eighty-eight year old 
female not only increases the risk of drug-to-drug interactions but also heightens risk 
factors for medical conditions that she may already be prone to getting (Scarpignato, 
Gatta, Zullo, & Blandizzi, 2016). For this reason, evaluation of the appropriateness of this 
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prescription begins by reviewing both long and short-term adverse outcomes associated 
with proton-pump inhibitor use.  
Adverse Outcomes 
Short-term adverse outcomes with proton pump inhibitors include side effects, 
such as diarrhea, abdominal pain, headache, and constipation (Scholl, Dellon, & Shaheen, 
2011). These complaints are typically short-lived and are often relieved by decreasing 
PPI dose or discontinuing. Drug-to-drug interactions are also common with PPI use 
(Scarpignato, et al., 2016). These interactions may be especially true in the case of 
omeprazole due to its action on CYP34A and CYP2C19. Again, this expected finding 
could easily be relieved with discontinuation of the medication and avoidance of 
polypharmacy. 
Less common, but of more concern, are the increased risks of enteric infections, 
such as Clostridium difficile and community-acquired pneumonia associated with PPI 
exposure (Heidelbaugh, Kim, Chang, & Walker, 2012). These adverse outcomes may be 
of greater concern in elderly patients, such as the case described above, due to their age 
and the dangers associated in this population with morbidity and mortality. 
Unfortunately, short-term adverse outcomes are not the only concern as research 
shows that the majority of patients prescribed a PPI will stay on a PPI (Scarpignato, et al., 
2016). Inappropriate long-term PPI use is even more common in the elderly. This type of 
drug therapy is associated with increased risks of dementia, bone fractures, mineral and 
vitamin malabsorption, and chronic kidney disease. Given the seriousness of many of 
these conditions, further examinations of these adverse events as they relate to the clinical 
case are discussed. 
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Dementia. A study examining the PPI associated risk of dementia revealed that 
the likelihood of developing dementia is 44% higher amongst PPI users compared to non-
users (Freedberg, st al., 2017). Participants who occasionally used PPIs had a 16% 
increase of dementia development. This association can also be related to increased 
Alzheimer’s risk. According to statistics derived from the Center of Disease Control, in 
2014 Alzheimer’s was listed as the third leading cause of death amongst individuals over 
the age of 85 (Heron, 2016). Given E.L’s age, this adverse outcome must be taken into 
consideration when discussing possible long-term therapy.  
Bone Fractures. In addition to increased mortality risk associated with dementia, 
women over the age of 65 who incur a hip fracture are also at in increased risk of death 
within the following year. A meta-analysis of eighteen studies revealed that PPIs are 
associated with a modestly increased risk of fractures (Zhou, Huang, Li, Sun, et al., 
2016). Hip fractures, in particular, were increased in both short and long term PPI use, 
although one study showed increased rates with higher dosages and longer time frames 
(Heidelbaugh, 2013). Given that hip fractures in elderly women significantly increases 
morbidity and mortality within the following year, this is something to be mindful of in 
appropriate follow-up. E.L is already at an increased risk due to her history of smoking, 
her given age and her need for a walker with ambulation.  
Mineral and vitamin malabsorption. Although several studies debate which 
vitamins and minerals are affected with PPI use and the significance, two areas in 
particular are of concern for E.L. First, calcium absorption is thought to contribute to the 
increased risk of fractures as previously mentioned (Zhou, et al., 2016). Yet, review of 
calcium supplementation of those taking PPIs did not show any significance to suggest 
PROTON PUMP INHIBITOR CASE REPORT 
 
10 
adding it into current guidelines. The same was true regarding evaluation of vitamin B12, 
of which a deficiency is thought to affect upwards of 20% of the elderly population 
already (Heidelbaugh, 2013). In fact, PPI use was associated with a 2-4 times increase of 
vitamin B12 deficiency, and further risk association with this medication occurred with 
increased age (Freedberg, et al., 2017; Heidelbaugh, et al., 2012). Many elderly already 
exhibit contributing factors to several nutritional deficiencies with E.L being no 
exception.  
Chronic Kidney Disease. Medical and social history to include long-standing 
tobacco use and hypertension are primary contributing factors to developing chronic 
kidney disease (CKD). E.L’s family history of heart disease may also suggest an 
increased risk. In addition, new studies are now evaluating the effect that PPIs may also 
have on this condition. A recent report published in Medscape (2016), suggests that PPIs 
contribute to elevated serum creatinine, increased glomerular filtration rates (GFR), and 
ultimately CKD when compared to H2-blocker use or no antacid use (Harrison, 2016). In 
other words, E.L’s new prescription may also increase her associated risk factors for 
CKD. 
Although literature reviewed may differ in the degree to which PPIs contribute to 
the adverse outcomes as stated above, many researchers agree that additional 
interventions do not result in any benefit (Freedberg, et al., 2017). Furthermore, all 
literature concurred that the best way to avoid adverse outcomes is to follow associated 
guidelines and minimize inappropriate PPI use. 
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Minimizing Inappropriate PPI Use 
Research shows that adhering to guidelines is one of the safest and most rational 
ways to utilize PPIs, minimizing adverse effects (Scarpignato, et al., 2016). E.L. is 
appropriately prescribed once daily omeprazole 20mg, aligning with current guidelines 
published with the American College of Gastroenterology (Katz, Gerson, & Vela, 2013). 
However, if her PCP fails to trial her off of this PPI at her eight-week follow-up, she will 
become one of the 25% to 70% of people that are inappropriately prescribed a PPI 
(Boghossian, Rahid, Thompson, Welch, et al., 2017). If there is no longer an indication 
for E.L to be taking a PPI, then she is only exposed to the risk factors and will have no 
benefit. 
Guidelines. Following guidelines will help to avoid inappropriate use of PPIs 
and, in turn, decrease adverse effects. Many guidelines agree that initial therapy of GERD 
should be a PPI, but they also suggest completing a trial off the medications after eight 
weeks (Katz, Gerson, & Vela, 2013). If symptoms return, guidelines suggest reinstating 
PPIs at the lowest dose possible or consider alternative therapy. To prevent adverse 
outcomes, guidelines suggest that providers consider step down therapy, utilizing 
H2blockers, alternating the timing of medication and implementing lifestyle factors 
(Katz, Gerson, & Vela, 2013). All of these recommendations help to decrease 
overutilization and unwarranted effects of PPI use. Full details of GERD guidelines can 
be found in Appendix B. 
Short-term. Several strategies that align with current guidelines can be used to 
address associated adverse outcomes with short-term PPI use. Often, these strategies 
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begin with ensuring the patient is utilizing the minimal dosage necessary and taking 
medications as intended in combination with alleviating lifestyle factors. 
 To address these points, often education is needed for both the patient and 
provider in regards to short-term therapy. Providers should be reminded to follow 
guidelines that suggest the minimal dosage for all PPI users (Katz, Gerson, & Vela, 
2013). To avoid increasing the dose, providers should ensure that the patients are taking 
these medications appropriately. It may be that patients are not taking the medications at 
appropriate times or not as intended, which could be dampening the PPI effectiveness. 
Evaluation of polypharmacy should also occur to ensure that it is not another reason the 
medications are not being effective. 
 Addressing lifestyle factors that may alleviate symptoms is also suggested for all 
PPI users. Research recommends avoiding common dietary triggers individualized for the 
patient and/or known to increase stomach PH (Katz, Gerson, & Vela, 2013). Exercise and 
weight loss may also be of benefit; one study demonstrated that 54% of overweight/obese 
subjects who lost weight were able to come off of PPI therapy and that 32% more were 
able to cut their dosage in half (Scarpignato, et al., 2016). In other words, adding lifestyle 
management may prevent the need for longer therapy and/or increased dosages short 
term. 
Long-term. To decrease the risk of adverse outcomes associated with long-term 
use, the provider must first evaluate the appropriateness of the prescription (Katz, 
Gerson, & Vela, 2013). Unfortunately, re-evaluation of PPI use is not always done as we 
note the debate of the provider in the case study being evaluated. In fact, in one study 
nearly half of PPI users stated they were never asked in follow-up about their upper GI 
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symptoms; therefore, never had an opportunity to discuss stepping down or coming off 
from therapy (Heidelbaugh, et al., 2012). Additionally, providers see patients staying on 
PPIs simply because they were not educated as to when to stop therapy during initial 
prescription. As little as 1 in 10 PPI users are educated on when to discontinue PPI use 
from their providers (Haastrup, Paulsen, Begtrup, Hansen, & Jarbøl, 2014). It is clear that 
the very first intervention necessary to prevent inappropriate PPI use is to ensure that 
PCPs are providing education and re-evaluation. Providing E.L with additional 
anticipatory guidance at this intial visit may help to address thisconcern. 
 If long-term use is deemed necessary, secondary interventions are aimed at those 
similar to prevention of short-term effects. Reducing these adversaries can be done 
through dosage deduction and education as discussed earlier. If patient has never been 
trialed at a lower dosage, research suggests cutting the standard dose of PPI in half to see 
if symptoms remain in control (Walsh, Kwan, Marr, Papoushek, & Lyon, 2016). Often 
symptoms remain in control at this lower dosage. In one study of long-term PPI users, 
thirty to fifty percent of participants remained symptom free on reduced dosages at three 
months after prescription change (Haastrup, et al., 2014). These results included 
participants with associated GERD risk factors similar to E.L’s to include smoking, 
alcohol intake, and increased BMI.  
In addition to dosage reduction, step down therapy, intermittent use, or on-
demand therapy are also suggested as interventions, according to guidelines (Katz, 
Gerson, & Vela, 2013). These strategies include stepping down therapy to H2 blockers or 
minimal PPI use, utilizing intermittent treatments, according to symptoms and/or taking 
PPIs only when symptoms arise or “on-demand.” Despite the fact that many patients are 
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satisfied with on these types of therapy, few clinicians actually utilize them (Freedberg, 
Kim, & Yang, 2017; Heidelbaugh, 2013). In regards to step-down treatment, one study 
revealed that only 58.5% of patients currently on a PPI had ever tried H2 blockers for 
symptom relief (Walsh, et al., 2016). Still, implications for such therapies are clear as the 
result is decreased exposure to PPI use and thus decreased risk for adverse outcomes. 
If re-evaluation of patients prescribed PPIs does not reveal an appropriate long-
term reason as suggested by guidelines in Appendix B, then the next step is to de-
prescribe. In the management of mild to moderate GERD, up to 64% of individuals were 
able to successfully come off of their PPIs (Haastrup, et al., 2014). In literature 
examining de-prescribing of PPIs, consensus shows that tapering seems to be the best 
method tolerated amongst patients. There still remains debate, however, on the best way 
to achieve this result. 
Challenges to Minimizing PPI Use 
Despite the strong evidence suggesting minimizing inappropriate PPI use, still 
challenges exist out in practice to appropriately do so. One of them may be that PCPs 
often lack the time and knowledge to intervene (Walsh, et al., 2016). With acute clinical 
visits, if a patient’s medication list includes PPIs with GERD symptom relief, oftentimes 
it is viewed as the medication working and, therefore, seen as no need to address. In 
addition, a common challenge with PPI use in particular includes its availability for over-
the-counter use. In this case, the provider may not even be aware that their patient has 
been utilizing PPIs. 
Another challenge includes additional adverse effects associated with the abrupt 
stopping of PPIs: hypergastrinemia and rebound acid hypersecretion (Hasstrup et al., 
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2014). These conditions after long-term PPI use may cause severe dyspeptic symptoms, 
sometimes worse than those experienced prior to initiation of PPI therapy (Niv, 2011). To 
combat this challenge, some literature suggests that utilizing a tapering approach may 
help to alleviate these discomforts (Haastrup, et al., 2014; Niv, 2011). As mentioned 
previously however, no present research has guidelines of how to complete tapering of 
PPIs. 
Conclusion 
After reviewing possible adverse effects of PPI use, it is evident that minimizing 
inappropriate PPI therapy is crucial in the primary care setting. Reevaluating the need for 
long-term PPI therapy for E.L’s treatment of GERD symptoms and trial off therapy is 
strongly warranted in this clinical case study. Guidelines associated with GERD 
treatment agree, and adhering to these guidelines is the safest way to utilize this class of 
medication. Yet, providers still question this practice and often neglect to de-prescribe or 
minimize PPI use, and the result is an inappropriately prescribed medication for 
symptoms that the patient may not be having. In the case of E.L, an otherwise healthy 
elderly female, there is no need to increase the risk of medical conditions commonly 
associated with increased morbidity and mortality in this population. The clinician’s 
better choice is to use alternatives as recommended to decrease the need for PPI use and 
thus decrease any risk for adverse events. 
Learning Points 
• PPIs are often inappropriately prescribed. Adhering to guidelines is the best and 
safest way to ensure PPIs are being utilized appropriately to avoid adverse 
outcomes. 
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• Proton-pump inhibitors are associated with serious adverse effects for both short 
and long-term use. If patients are inappropriately utilizing PPIs, they are only 
being exposed to the risk factors with no benefits. 
• Education to patients on appropriate PPI use including anticipatory guidance, 
correct administration, and additional lifestyle factors may help to minimize 
adverse events and inappropriate PPI use. 
• Education to providers is crucial to ensure appropriate PPI therapy. This 
education should include suggestions for evaluation of all patients currently on 
PPIs for de-prescribing, follow-up for new PPI users, and use of step-down, 
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Electronic Medical Record for E.L. 
 
Name:       E.L      Age: 88 Date/Time of Encounter: 3/10/2017 
Gender: Female Race: Caucasian Contact Information: XXXXXX 
Source of Information: Patient is primary source of information and considered a 
reliable resource. 
History 
Chief Concern: Cough that won’t go away. Treated for bronchitis about two months 
ago. 
History of Present Illness: EL presents to clinic with a primary complaint of a cough. 
Patient states that the cough began about “2-3 months ago” and that she does not recall 
any triggers at that onset. She states the cough sits in the middle of her chest and is 
sometimes associated with a “sour taste” in her mouth. She denies any production with 
this cough, although she does mention a “burning” sensation at times. She describes the 
overall characteristics as “irritating” more than anything. She mentions that the cough has 
been there daily since its onset but specifically is worse at night. She denies any exposure 
to anyone who has been sick in association with this complaint. She has tried a humidifier 
to help with symptom relief as well as some “cough syrup and inhalers” prescribed at 
another facility for possible bronchitis. She notes that none of these treatments have 
helped at this time. She denies any drainage from eyes, ears or nasal passages. She does 
mention a sore throat associated with this complaint. 
Patient denies having similar symptoms as stated above in the past, although when asked 
about reflux, she does mention a history of “heartburn” for which she takes Tums. She 
also mentions drinking “a pot of coffee” every morning and frequently eating after 8pm 
prior to going to bed in the evening. EL is not particularly concerned about the severity of 
this cough interfering with her daily activities; however, she mentions it being more 
bothersome with interruption of sleep. She denies chest pain or shortness of breath. She 
denies any other complaints at this time. 
Past Medical History:  
1. Hypertension 
Immunizations- Up to date, seasonal flu shot obtained 
 
Family History: Patient is unsure if there is any history of gastroesophageal disease or 
upper GI disorders. She does mention a family history of heart disease, diabetes and 
colon cancer in first and second-degree relatives, although specifics on who are not 
disclosed. 
 




1. Lisinopril 10mg PO daily for hypertension 
2. Tums, 2 tablets as needed for heartburn relief 
 
Allergies: No known allergies to drugs, environment, or food 
Social History: Elderly retired female who lives with daughter in town. She currently 
denies any tobacco products although she mentions that she did quit using cigarettes 
about “10 years ago.” She mentions occasionally having 1-2 beers a night and denies any 
other illicit drug use. 
Review of Systems 
Constitutional: Patient denies generalized weakness, fatigue, or fever. 
Mental Health: No changes in social life factors, mood, memory, or sleep. Patient does 
note occasionally waking up from cough and “sour taste” in mouth at night. 
Skin, Hair, Nails: Denies any skin changes associated with acute illness. 
HEENT: Denies frequent headaches, swollen glands or lymph nodes. Denies visual or 
hearing changes, patient does have visual aids. Denies drainage or pain from eyes, ears, 
nose, and throat. Does mention sore throat and “sour taste” in mouth associated with 
cough as described in HPI. 
Endocrine: No thyroid conditions or diabetic concerns 
Chest & Lungs: No shortness of breath at rest. Patient denies increased work of 
breathing or wheezing. Positive for cough as described in HPI. No hemoptysis.  
Cardiovascular: No chest pain or palpitations. No swelling in lower extremities, calf 
tenderness, or warmth. 
Gastrointestinal: Denies nausea, vomiting, constipation, diarrhea, or complaints of pain.  
Physical Examination Vitals: BP 130/80, Pulse 76, RR 16, Temp. 97.8 
General Appearance: Patient is a well-developed, well-groomed, white female 
appearing her stated age of 88. She presents with calm demeanor, no signs of acute 
distress, sitting in exam room dressed appropriately. She cooperates throughout exam. 
Mental Status: Alert and orientated X4, with appropriate thoughts and mood. Responds 
appropriately throughout exam with no signs of depression or anxiety. 
Skin, Hair, Nails: Skin warm, dry and intact with appropriate color for race throughout 
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body. No abrasions, rashes or contusions noted. 
HEENT: Head is midline and normocephalic without facial or scalp tenderness. Jugular 
venous distension not observed. Eyes: Pupils equal, round, reactive to light and 
accommodation. Ears: Auricles symmetrical, no nodules noted. Otoscopic findings 
indicate scant amount of cerumen in ears, no drainage or lesions. TMs pearly gray with 
visible cone of light and bony landmarks. No redness or effusion present. Nose: External 
nose midline with nares patent. No discharge noted. Mouth & Throat: Lips and oral 
cavity intact with moist, pink mucosa. Neck: Neck supple, no cervical lymphadenopathy 
noted. Thyroid midline with no nodules noted. 
Chest & Lungs: Respirations of regular rate and rhythm without labor. Lungs sounds 
clear, no adventitious lung sounds present upon auscultation. Auscultation during patient 
cough appears dry. 
Cardiovascular: Heart rate of regular rate and rhythm with S1, S2 auscultated; no 
murmurs present. Peripheral pulses equal, +2 bilaterally, no edema in lower extremities. 
Capillary refill of <2seconds.  
Abdomen: Abdomen soft, round, nontender. Bowel sounds present and normoactive in 
all four quadrants. Negative for bruits. No CVA tenderness. No organomegaly. 
Musculoskeletal: Patient able to get on and off examination table with minimal 
assistance. Gait is slow and shuffled, utilizing a walker for assistance. 
Radiology: Chest Xray completed is unremarkable. 
 
Assessment: 
1. K21 Gastro-esophageal reflux disease 
 
Plan: 
1. Omeprazole 20mg prescribed and sent to the pharmacy of her choice. Instructed 
patient to stop taking the Tums at this time and to begin the omeprazole once 
daily starting today. Educated patient on adverse effects and all questions 
addressed. 
2. Discussed lifestyle factors contributing to condition. Included recommendations 
on diet, exercise and weight loss as tolerated. Educated on elevating head of bed 
or increasing amount of pillows. Also discussed avoidance of trigger foods such 
as caffeine, alcohol, citrus fruits, spicy foods or anything else that she notices 
contributes to her personal symptom onset. Patient is also encouraged to eat 
earlier in the evening prior to bedtime. 
3. Patient is instructed to return to clinic in 8 weeks for follow-up regarding her 
GERD or sooner if symptoms do not improve or get worse. 
 
Information electronically recorded and signed by:  Kimberly Williams, RN BSN, FNP 
Student 






Management of GERD 
1. Weight loss is recommended for GERD patients who are overweight or have had recent 
weight gain. (Conditional recommendation, moderate level of evidence) 
2. Head of bed elevation and avoidance of meals 2–3 h before bedtime should be 
recommended for patients with nocturnal GERD. (Conditional recommendation, low level of 
evidence) 
3. Routine global elimination of food that can trigger reflux (including chocolate, caffeine, 
alcohol, acidic and/or spicy foods) is not recommended in the treatment of GERD. 
(Conditional recommendation, low level of evidence) 
4. An 8-week course of PPIs is the therapy of choice for symptom relief and healing of erosive 
esophagitis. There are no major differences in efficacy between the different PPIs. (Strong 
recommendation, high level of evidence) 
5. Traditional delayed release PPIs should be administered 30–60 min before meal for maximal 
pH control. (Strong recommendation, moderate level of evidence). Newer PPIs may offer 
dosing flexibility relative to meal timing. (Conditional recommendation, moderate level of 
evidence) 
6. PPI therapy should be initiated at once a day dosing, before the first meal of the day. (Strong 
recommendation, moderate level of evidence). For patients with partial response to once daily 
therapy, tailored therapy with adjustment of dose timing and/or twice daily dosing should be 
considered in patients with night-time symptoms, variable schedules, and/or sleep disturbance. 
(Strong recommendation, low level of evidence). 
7. Non-responders to PPI should be referred for evaluation. (Conditional recommendation, low 
level of evidence, see refractory GERD section). 
8. In patients with partial response to PPI therapy, increasing the dose to twice daily therapy or 
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switching to a different PPI may provide additional symptom relief. (Conditional 
recommendation, low level evidence). 
9. Maintenance PPI therapy should be administered for GERD patients who continue to have 
symptoms after PPI is discontinued, and in patients with complications including erosive 
esophagitis and Barrett’s esophagus. (Strong recommendation, moderate level of evidence). 
For patients who require long-term PPI therapy, it should be administered in the lowest 
effective dose, including on demand or intermittent therapy. (Conditional recommendation, 
low level of evidence) 
10. H2-receptor antagonist (H2RA) therapy can be used as a maintenance option in patients 
without erosive disease if patients experience heartburn relief. (Conditional recommendation, 
moderate level of evidence). Bedtime H2RA therapy can be added to daytime PPI therapy in 
selected patients with objective evidence of night-time reflux if needed, but may be associated 
with the development of tachyphlaxis after several weeks of use. (Conditional 
recommendation, low level of evidence) 
11. Therapy for GERD other than acid suppression, including prokinetic therapy and/or 
baclofen, should not be used in GERD patients without diagnostic evaluation. (Conditional 
recommendation, moderate level of evidence) 
12. There is no role for sucralfate in the non-pregnant GERD patient. (Conditional 
recommendation, moderate level of evidence) 
13. PPIs are safe in pregnant patients if clinically indicated. (Conditional recommendation, 
moderate level of evidence) 
Note:  Summary and Strength of Recommendation for GERD (Katz, P., Gerson, L. & 
Vela, M., 2013, p. 309). 
